Bristol-Myers Squibb Management
Management criteria checks 3/4
Bristol-Myers Squibb's CEO is Chris Boerner, appointed in Nov 2023, has a tenure of less than a year. total yearly compensation is $8.46M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth $4.47M. The average tenure of the management team and the board of directors is 2.3 years and 4.5 years respectively.
Key information
Chris Boerner
Chief executive officer
US$8.5m
Total compensation
| CEO salary percentage | 14.9% |
| CEO tenure | less than a year |
| CEO ownership | 0.005% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Bristol-Myers Squibb: A Lost Decade?
May 03Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S
Apr 29
Is Bristol Myers Squibb A Buy At These Bottom Levels?
Apr 22Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Apr 12Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
Apr 02Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 21Bristol-Myers Squibb Is Not A Buy For Me
Mar 19Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Mar 07Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 07We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative
Feb 20Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Feb 06Bristol-Myers Squibb: Massive Discount Spells Opportunity
Feb 04BMY: Might Be Approaching A Bottom In 2024
Jan 23Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings
Jan 16Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also
Jan 10Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Dec 31Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60
Dec 26Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now
Dec 19Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock
Dec 12Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60
Dec 11Bristol-Myers Squibb: The Patent Expiry Challenge
Nov 23Bristol Myers Squibb: Bright Future Ahead
Nov 17Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Nov 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$6b |
| Dec 31 2023 | US$8m | US$1m | US$8b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$7b |
| Dec 31 2022 | US$7m | US$1m | US$6b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$7m | US$1m | US$7b |
| Sep 30 2021 | n/a | n/a | -US$5b |
| Jun 30 2021 | n/a | n/a | -US$5b |
| Mar 31 2021 | n/a | n/a | -US$6b |
| Dec 31 2020 | US$6m | US$953k | -US$9b |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$563m |
| Mar 31 2020 | n/a | n/a | US$954m |
| Dec 31 2019 | US$6m | US$891k | US$3b |
Compensation vs Market: Chris's total compensation ($USD8.46M) is below average for companies of similar size in the US market ($USD13.59M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Boerner (52 yo)
less than a year
Tenure
US$8,461,833
Compensation
Dr. Christopher S. Boerner, also known as Chris, Ph.D. served as Chief Operating Officer at Bristol-Myers Squibb Company since April 26, 2023 to 2023 and served as its Executive Vice President since April...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | less than a year | US$8.46m | 0.0050% $ 4.5m | |
| Executive VP & CFO | 4.5yrs | US$7.17m | 0.0096% $ 8.6m | |
| Executive VP & General Counsel | 17.3yrs | US$5.92m | 0.022% $ 19.8m | |
| Executive VP | 4.9yrs | US$6.23m | 0.0030% $ 2.7m | |
| Executive VP and Chief Digital & Technology Officer | 2.3yrs | no data | 0.00026% $ 233.0k | |
| VP & Head of Investor Relations | no data | no data | no data | |
| Chief Compliance & Ethics Officer | less than a year | no data | no data | |
| Executive Vice President & Chief Human Resources Officer | less than a year | no data | 0.00013% $ 116.5k | |
| Head of Medical Affairs | no data | no data | no data | |
| Executive VP | no data | no data | 0.00080% $ 716.9k | |
| Senior Vice President of Major Markets | no data | no data | no data | |
| Executive Vice President of Global Product Development & Supply | 2.3yrs | no data | 0.00030% $ 268.9k |
2.3yrs
Average Tenure
53yo
Average Age
Experienced Management: BMY's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.3yrs | US$8.46m | 0.0050% $ 4.5m | |
| Independent Director | 12.3yrs | US$357.50k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$375.00k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$365.00k | 0% $ 0 | |
| Independent Director | 8.1yrs | US$359.68k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$329.97k | 0% $ 0 | |
| Lead Independent Director | 7.3yrs | US$425.00k | 0.0018% $ 1.6m | |
| Independent Director | 3.7yrs | US$365.00k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$371.68k | 0.00067% $ 600.4k | |
| Independent Director | 6.3yrs | US$344.74k | 0% $ 0 | |
| Independent Director | 2.9yrs | US$335.00k | 0% $ 0 |
4.5yrs
Average Tenure
62yo
Average Age
Experienced Board: BMY's board of directors are considered experienced (4.5 years average tenure).